https://orcid.org/0000-0002-6986-4777
References
- Nataraj MD, Basavaraj BU, Deepak AY. In-silico drug design approach for identification of antibacterial drug leads for treatment of gastric lymphoma. J. Chem. 2013;2(1):01–07.
- Amnerkar DN, Bhusari KP. Synthesis, anticonvulsant activity and 3D-QSAR study of someprop-2-eneamido and 1-acetyl-pyrazolin derivatives of amino-benzothiazole. Eur J Med Chem. 2010;45(1):149–159.
- Kitagawa H, Ozawa T, Takahata T, et al. Phenylimidazole derivatives as new inhibitors of bacterial enoyl-ACP reductase FabK. Bioorg Med Chem Lett. 2007;17(17):4982–4986.
- Ingle RG, Magar DD. Heterocyclic chemistry of benzimidazoles and potential activities of derivatives. Int J Drug Res Tech. 2011;1(1):26–32.
- Krishna Prasad PM, Kanvind SA, S R. Potent biological agent benzimidazole – a review. Int J Pharm Pharm Sci. 2016; 8(12):22–33.
- Sunil LH, Manish SB. In-silico docking based design and synthesis of [1H,3H] imidazo[4,5-b] pyridines as lumazine synthase inhibitors for their effective antimicrobial activity. J Pharm Bioall Sci. 2014;6:285–296.
- Swapna D, Prathyusha PV, Sucharitha D, et al. A review of P38 kinase inhibitors as anti-inflammatory drug targets. Int J Pharm Tech. 2010;2(1):86–101.
- Suresh N. In silico pharmacophore modeling and virtual screening to design potential p38 MAP kinase inhibitors as new leads. Int J Drug Design and Discovery. 2012;3(2):757–765.
- Narasimhan B, Sharma D, Kumar P. Benzimidazole: a medicinally important heterocyclic moiety. Med Chem Res. 2010;21(3):269–283.
- Moens U, Kostenko S, Sveinbjørnsson B. The role of mitogen-activated protein kinase-activated protein kinases (MAPKAPKs) in Inflammation. Genes (Basel)). 2013;4(2):101–133.
- Mader M, de Dios A, Shih C, et al. Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties . Bioorg Med Chem Lett. 2008;18(1):179–183.
- Revesz L, Di Padova FE, Buhl T, et al. SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors. Bioorg Med Chem Lett. 2002;12(16):2109–2112.
- Blake JF, Laird ER. Chapter 30: recent advances in virtual ligand screening. Annu Rep Med Chem. 2003;38:305–314.
- Becker OM, Dhanoa DS, Marantz Y, et al. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. J Med Chem. 2006;49(11):3116–3135.